CN111836635A - 肽交换蛋白 - Google Patents

肽交换蛋白 Download PDF

Info

Publication number
CN111836635A
CN111836635A CN201980018422.2A CN201980018422A CN111836635A CN 111836635 A CN111836635 A CN 111836635A CN 201980018422 A CN201980018422 A CN 201980018422A CN 111836635 A CN111836635 A CN 111836635A
Authority
CN
China
Prior art keywords
peptide
tapbpr
cells
cell
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201980018422.2A
Other languages
English (en)
Chinese (zh)
Inventor
路易丝·海伦·鲍尔
安德烈亚斯·海因里希·尼伦克斯
弗洛林·都铎·伊艾卡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge Enterprise Ltd
Original Assignee
Cambridge Enterprise Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1801323.5A external-priority patent/GB201801323D0/en
Priority claimed from GBGB1813737.2A external-priority patent/GB201813737D0/en
Application filed by Cambridge Enterprise Ltd filed Critical Cambridge Enterprise Ltd
Publication of CN111836635A publication Critical patent/CN111836635A/zh
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201980018422.2A 2018-01-26 2019-01-25 肽交换蛋白 Withdrawn CN111836635A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1801323.5A GB201801323D0 (en) 2018-01-26 2018-01-26 Peptide exchange protein
GB1801323.5 2018-01-26
GBGB1813737.2A GB201813737D0 (en) 2018-08-23 2018-08-23 Peptide exchange protein
GB1813737.2 2018-08-23
PCT/EP2019/051907 WO2019145509A1 (en) 2018-01-26 2019-01-25 Peptide exchange protein

Publications (1)

Publication Number Publication Date
CN111836635A true CN111836635A (zh) 2020-10-27

Family

ID=65234583

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980018422.2A Withdrawn CN111836635A (zh) 2018-01-26 2019-01-25 肽交换蛋白

Country Status (7)

Country Link
US (1) US12397036B2 (https=)
EP (1) EP3743093A1 (https=)
JP (2) JP2021515588A (https=)
CN (1) CN111836635A (https=)
AU (1) AU2019211121B2 (https=)
CA (1) CA3089154A1 (https=)
WO (1) WO2019145509A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11814420B2 (en) 2018-07-06 2023-11-14 The Regents Of The University Of California Peptide deficient-MHC class I/chaperone compositions and methods
EP4085069A1 (en) * 2020-01-03 2022-11-09 The Regents of The University of California Systems and methods for identification of mhc-i peptide epitopes
US12534510B2 (en) 2020-04-16 2026-01-27 The Regents Of The University Of California Peptide-receptive MHC-I complex compositions and methods
WO2023163980A1 (en) * 2022-02-22 2023-08-31 The Children's Hospital Of Philadelphia Systems and methods for chaperone-mediated ligand exchange on mhc-i and mhc-related molecules using chicken tapbpr
WO2026024596A1 (en) * 2024-07-22 2026-01-29 The Children's Hospital Of Philadelphia Methods of stimulating an immune response

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541104A (en) 1991-05-23 1996-07-30 Ludwig Institute For Cancer Research Monoclonal antibodies which bind to tumor rejection antigen precursor mage-1
US6235525B1 (en) 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
ES2225824T3 (es) 1992-08-31 2005-03-16 Ludwig Institute For Cancer Research Nonapeptido aislado derivado del gen mage-3 y presentado por hla-a1, y sus usos.
US6222012B1 (en) 1992-08-31 2001-04-24 Ludwig Institute For Cancer Research Isolated nonapeptides presented by HLA molecules, and uses thereof
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
WO1995023874A1 (en) 1994-03-01 1995-09-08 Ludwig Institute For Cancer Research Determination of cancerous conditions by mage gene expression
US6291430B1 (en) 1997-09-12 2001-09-18 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
US7060479B2 (en) * 1999-12-08 2006-06-13 Serono Genetics Institute, S.A. Full-length human cDNAs encoding potentially secreted proteins
US6692923B2 (en) * 1999-04-14 2004-02-17 Incyte Corporation Tapasin-like protein
AU2001260847A1 (en) 2000-05-24 2001-12-03 Genesis Research And Development Corporation Limited Compositions isolated from skin cells and methods for their use
US7947436B2 (en) * 2004-12-13 2011-05-24 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in the process of bone remodeling
JP2011518115A (ja) * 2008-01-28 2011-06-23 タップイミューン インコーポレイテッド 免疫応答を増強するためのタパシン増加
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card
CN111909278B (zh) 2014-01-27 2024-04-09 分子模板公司 Mhc i类表位递送多肽
CN107857819A (zh) * 2017-07-03 2018-03-30 江苏西迪尔生物技术有限公司 多功能融合蛋白及其应用
CN112469479B (zh) 2018-07-10 2024-08-13 康涅狄格大学 治疗癌症和自身免疫性疾病的试剂和方法

Also Published As

Publication number Publication date
WO2019145509A1 (en) 2019-08-01
US20210052695A1 (en) 2021-02-25
JP2024029012A (ja) 2024-03-05
EP3743093A1 (en) 2020-12-02
AU2019211121B2 (en) 2024-09-12
JP2021515588A (ja) 2021-06-24
US12397036B2 (en) 2025-08-26
AU2019211121A1 (en) 2020-08-27
CA3089154A1 (en) 2019-08-01

Similar Documents

Publication Publication Date Title
JP2024029012A (ja) ペプチド交換蛋白質
US10799534B2 (en) Enhancing the effect of car-engineered T cells by means of nucleic acid vaccination
US8518697B2 (en) Single chain trimers and uses therefor
AU2017330067B2 (en) T cells with increased immunosuppression resistance
KR20200039765A (ko) T 세포 변형
US20230074462A1 (en) Methods and compositions for stimulating immune response
JP2014509841A (ja) 癌を治療するための組成物および方法
US20040096429A1 (en) Method for producing cytotoxic T-cells
US20180179283A1 (en) T cell receptor like antibodies having fine specificity
US20240067699A1 (en) T-cell modulatory polypeptides and methods of use thereof
JP4587566B2 (ja) Ｈｌａクラスｉ分子と付着手段とを含む複合体を用いた、標的細胞に対するｔ細胞応答を作出又は強化する方法
JP2023548556A (ja) Ｅｇｆｒ抗原を標的とする操作されたｔ細胞受容体および使用方法
Braitbard et al. A new immunization and treatment strategy for mouse mammary tumor virus (MMTV) associated cancers
US7264965B2 (en) Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class I molecule and an attaching means
CN112041432A (zh) Foxp3靶向剂组合物以及用于过继细胞疗法的使用方法
KR20220083773A (ko) 암 항원을 포함하는 개선된 lamp 구축물
WO2018077242A1 (zh) 识别sage1抗原短肽的t细胞受体
Padula et al. Secreted heat shock protein gp96-Ig and OX40L-Fc combination vaccine enhances SARS-CoV-2 Spike (S) protein-specific B and T cell immune responses
US20260115272A1 (en) Methods and compositions for stimulating immune response
US20250073333A1 (en) Peptides and engineered t cell receptors targeting fanci, rad51, and pbk antigens and methods of use
WO2022166904A1 (zh) 一种识别hpv的t细胞受体
CN118103062A (zh) 靶向sars-cov-2抗原的肽和工程化t细胞受体及其使用方法
JP2023537558A (ja) 目的の抗原にｃａｒ ｔ細胞をリダイレクトするためのアダプター分子
CN117425482A (zh) 靶向egfr抗原的经改造t细胞受体和使用方法
Myers Custom designed MHC binding peptides for cancer immunotherapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20201027